Tom Boterberg

The citrus methoxyflavone tangeretin affects human cell-cell interactions.

Intensity modulated radiation therapy for oropharyngeal and oral cavity tumors: clinical use and experience.

Short term toxicity profile for 32 sinonasal cancer patients treated with IMRT. Can we avoid dry eye syndrome?

Postoperative radiotherapy for adenocarcinoma of the ethmoid sinuses: treatment results for 47 patients.

Does the addition of glutamine to total parenteral nutrition have beneficial effect on the healing of colon anastomosis and bacterial translocation after preoperative radiotherapy?

Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience.

Pain control by ionizing radiation of bone metastasis.

Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer.

Bowes melanoma cells secrete heregulin, which can promote aggregation and counteract invasion of human mammary cancer cells.

Automatic generation of a plan optimization volume for tangential field breast cancer radiation therapy.

Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation.

Postoperative intensity-modulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients.

Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit.

Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model.

Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer.

Radiation of the rat brain suppresses seizure-induced neurogenesis and transiently enhances excitability during kindling acquisition.

Intensity-modulated radiotherapy for cervical lymph node metastases from unknown primary cancer.

F-18 fluorodeoxyglucose PET/CT scanning in the diagnostic work-up of a primary pericardial mesothelioma: a case report.

Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update.

Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.

Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory.

Regional relapse after intensity-modulated radiotherapy for head-and-neck cancer.

Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent.

Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer.

IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival.

Radiotherapy for marginally resected, unresectable or recurrent giant cell tumor of the bone: a rare cancer network study.

Late-onset post-irradiation vasculopathy of the posterior cerebral vasculature.

Hypofractionated frameless stereotactic intensity-modulated radiotherapy with whole brain radiotherapy for the treatment of 1-3 brain metastases.

Systematic review of dose--volume correlates for structures related to late swallowing disturbances after radiotherapy for head and neck cancer.

Cell aggregation assays.

Validation of the Freund Clock Drawing Test as a screening tool to detect cognitive dysfunction in elderly cancer patients undergoing comprehensive geriatric assessment.

High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: disease control, survival and toxicity.

MRI-guided 3D conformal arc micro-irradiation of a F98 glioblastoma rat model using the Small Animal Radiation Research Platform (SARRP).

Hair-sparing whole brain radiotherapy with volumetric arc therapy in patients treated for brain metastases: dosimetric and clinical results of a phase II trial.

(18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.

Echium oil is not protective against weight loss in head and neck cancer patients undergoing curative radio(chemo)therapy: a randomised-controlled trial.

Intensity-modulated radiotherapy for early-stage glottic cancer.

Tumor recurrence and in-field control after multimodality treatment of locally advanced esophageal cancer.

Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer.

G-8 indicates overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy.

Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents.

Implementation of uHear™--an iOS-based application to screen for hearing loss--in older patients with cancer undergoing a comprehensive geriatric assessment.

Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment.

Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats.

Age and cellular context influence rectal prolapse formation in mice with caecal wall colorectal cancer xenografts.

Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis.

18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.

In Vivo DCE-MRI for the Discrimination Between Glioblastoma and Radiation Necrosis in Rats.

Distant metastases in head and neck cancer.

Long-term outcome of 18 F-fluorodeoxyglucose-positron emission tomography-guided dose painting for head and neck cancer: Matched case-control study.

The use of uHear™ to screen for hearing loss in older patients with cancer as part of a comprehensive geriatric assessment.

Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF-1R activation.